These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dilated cardiomyopathy, are a few drinks allowed? Balk AH Eur Heart J; 2000 Feb; 21(4):267-9. PubMed ID: 10653673 [No Abstract] [Full Text] [Related]
5. Diabetes does not affect ventricular repolarization and sudden cardiac death risk in patients with dilated cardiomyopathy. Vrtovec B; Fister M; Poglajen G; Starc V; Haddad F Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S146-50. PubMed ID: 19250080 [TBL] [Abstract][Full Text] [Related]
6. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C; Eur Heart J; 2004 Aug; 25(16):1454-70. PubMed ID: 15302105 [No Abstract] [Full Text] [Related]
7. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor. Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389 [TBL] [Abstract][Full Text] [Related]
8. Recurrence of ventricular arrhythmias in patients with non-ischaemic dilated cardiomyopathy: evidence-based predictors. Dułak E; Lubiński A; Bissinger A; Przybylski A; Sterlinski M; Filipecki A; Pazdyga A; Zienciuk A; Kempa M; Królak T; Szwed H; Trusz-Gluza M; Kargul W Kardiol Pol; 2009 Aug; 67(8):837-44. PubMed ID: 19784881 [TBL] [Abstract][Full Text] [Related]
10. [Secondary prevention after an acute myocardial infarct. Adrenergic beta-blockers, angiotensin-converting enzyme inhibitors and statins for everyone?]. Morais J Rev Port Cardiol; 2000 Jan; 19(1):99-105. PubMed ID: 10731795 [No Abstract] [Full Text] [Related]
11. Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic. Nayak D; Aronow WS Cardiol Rev; 2005; 13(2):95-7. PubMed ID: 15705260 [TBL] [Abstract][Full Text] [Related]
12. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. Grimm W; Alter P; Maisch B Herz; 2004 May; 29(3):348-52. PubMed ID: 15167963 [TBL] [Abstract][Full Text] [Related]
13. [Peculiarities of cardiac failure treatment in diffuse myocarditis and dilated cardiomyopathy]. Gurevich MA; Iankovskaia MO; Gordienko BV; Mravian SR; Grigor'eva NM Klin Med (Mosk); 1997; 75(1):48-50. PubMed ID: 9082062 [No Abstract] [Full Text] [Related]
14. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. Goldberger JJ; Subacius H; Schaechter A; Howard A; Berger R; Shalaby A; Levine J; Kadish AH; J Am Coll Cardiol; 2006 Sep; 48(6):1228-33. PubMed ID: 16979011 [TBL] [Abstract][Full Text] [Related]